Cita APA (7a ed.)

Y, S., T, N., A, U., K, Y., M, M., K, Y., . . . Y, I. (2018). Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis. Dove Medical Press.

Cita Chicago Style (17a ed.)

Y, Seko, et al. Efficacy and Safety of Canagliflozin in Type 2 Diabetes Mellitus Patients with Biopsy-proven Nonalcoholic Steatohepatitis Classified as Stage 1–3 Fibrosis. Dove Medical Press, 2018.

Cita MLA (8a ed.)

Y, Seko, et al. Efficacy and Safety of Canagliflozin in Type 2 Diabetes Mellitus Patients with Biopsy-proven Nonalcoholic Steatohepatitis Classified as Stage 1–3 Fibrosis. Dove Medical Press, 2018.